Your browser doesn't support javascript.
loading
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?
Geissler, Klaus; Jäger, Eva; Barna, Agnes; Sliwa, Thamer; Knöbl, Paul; Schwarzinger, Ilse; Gisslinger, Heinz; Valent, Peter.
Affiliation
  • Geissler K; 5 Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria klaus.geissler@wienkav.at.
  • Jäger E; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Barna A; Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria.
  • Sliwa T; 3 Medical Department, Hanusch Hospital, Vienna, Austria.
  • Knöbl P; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
  • Schwarzinger I; Department of Laboratory Medicine, Medical University of Vienna, Austria.
  • Gisslinger H; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
  • Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.
Haematologica ; 101(12): e492, 2016 12.
Article in En | MEDLINE | ID: mdl-27903714
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Myeloproliferative Disorders / Neoplasms Limits: Humans Language: En Journal: Haematologica Year: 2016 Document type: Article Affiliation country: Austria
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Myeloproliferative Disorders / Neoplasms Limits: Humans Language: En Journal: Haematologica Year: 2016 Document type: Article Affiliation country: Austria